<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>HBM Holdings Ltd. ( (HK:2142) ) has shared an announcement. HBM Holdings Ltd. disclosed that independent non-executive director Dr. Xiaoping Ye is under investigation by the China Securities Regulatory Commission over alleged violations related to information disclosure on shareholding changes in Hangzhou Tigermed Consulting Co., Ltd. Dr. Ye, who does not participate in HBM’s day-to-day management, has pledged to cooperate with regulators and comply with disclosure rules. The board said HBM’s operations remain normal and does not expect the probe to affect the group’s business, while promising further updates as the investigation progresses. Shareholders and potential investors have been urged to exercise caution when dealing in the company’s shares amid the ongoing regulatory inquiry. The most recent analyst rating on (HK:2142) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page. More about HBM Holdings Ltd. HBM Holdings Ltd. is a Cayman Islands–incorporated company listed in Hong Kong, operating through a group structure. Its board consists of executive and independent non-executive directors, with oversight of the company’s strategic direction and compliance with Hong Kong listing and securities regulations. Average Trading Volume: 3,391,318 Technical Sentiment Signal: Buy Current Market Cap: HK$11.72B </div>

516500

560600

510660

HBM Holdings Ltd. announced that its independent non-executive director, Dr. Xiaoping Ye, is under investigation by the China Securities Regulatory Commission for alleged information disclosure violations. The company stated that Dr. Ye does not engage in daily management and will cooperate with regulators. HBM's operations are reported to be normal, with no expected impact from the probe. Shareholders are advised to exercise caution during the inquiry. The latest analyst rating for HBM stock is a Buy, with a price target of HK$17.00.

Tip Ranks

ChinaAMC CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

HBM HOLDINGS-B

Tigermed

TIGERMED

HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations